Who may participate

This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:   

  • Willing and able to travel to our study facility in Brussels, Belgium
  • Able to comply with study appointments and procedures
  • Body mass index (BMI) of 16 to 32 kg/m2; and a total body weight >50 kg.
  • Additional criteria for participants to be enrolled in the Japanese Cohort only: Participants who have 4 Japanese biologic grandparents born in Japan; body weight >45 kg. 

Condition

Healthy

Age

18 to 65

Sex

Male and Female

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium. The study consists of 3 Parts A, B and C, of which you will join only Part C.  

  • Part C Single Dose Cohort 3 is planned to last for approximately 15-18 weeks. 
  • Cohort 7 is an optional Japanese Cohort. If you join the Japanese Cohort, this will last for approximately 9 weeks. 

  • Part C Multiple Dose is planned to last for approximately 11 weeks.

     

Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood and urine.  

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.

See calendar

Long-term follow-up  

A follow-up call at the end of the study 

How long is the study?

11 weeks

Compensation

For participation in Part C Cohort 3: € 6145.00